Cincor Pharma, Inc.
(NASDAQ : CINC)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc. -4.28%50.530.9%$1774.38m
JNJJohnson & Johnson -3.01%159.900.7%$973.09m
ABBVAbbVie, Inc. -1.30%130.261.9%$883.80m
MRKMerck & Co., Inc. -2.88%77.680.7%$846.95m
BMYBristol-Myers Squibb Co. -2.58%61.901.0%$648.88m
LLYEli Lilly & Co. -2.58%236.791.1%$603.24m
AZNAstraZeneca Plc -4.77%56.281.0%$226.50m
NVSNovartis AG -3.34%84.120.2%$185.07m
GSKGlaxoSmithKline Plc -2.63%43.920.2%$166.66m
NVONovo Nordisk A/S -1.38%94.050.1%$145.08m
VTRSViatris, Inc. -2.31%14.200.0%$133.69m
RGENRepligen Corp. 1.44%186.456.7%$100.39m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. 5.57%116.210.0%$77.84m
SNYSanofi -1.56%50.440.2%$64.51m
IMMXImmix Biopharma, Inc. -9.27%4.090.0%$64.49m

Company Profile

CinCor Pharma, Inc. operates as a clinical-stage biopharmaceutical company focused on developing its clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases. The firm is developing CIN-107 for the treatment of multiple diseases where aldosterone plays a significant role in disease pathophysiology, including hypertension and primary aldosteronism; as well as its utility in ameliorating complications of chronic kidney disease. The company was founded by Jon Isaacsohn and Catherine Pearce on March 28, 2018 and is headquartered in Boston, MA.